We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+41.17%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.01B
AUM Growth
+$219M
Cap. Flow
+$20.1M
Cap. Flow %
1.99%
Top 10 Hldgs %
55.14%
Holding
55
New
15
Increased
6
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$36.3M
2
GNFT
Genfit
GNFT
+$28.4M
3
EPZM
Epizyme, Inc
EPZM
+$24.3M
4
PTCT icon
PTC Therapeutics
PTCT
+$19.8M
5
CTMX icon
CytomX Therapeutics
CTMX
+$14.2M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$24.7M
2
CYTK icon
Cytokinetics
CYTK
+$20.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$14.7M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.3M 1.02%
+200,000
New +$8.64M
FOMX
27
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$10.1M 1%
2,697,133
-1,350,428
-33% -$5.06M
LRMR icon
28
Larimar Therapeutics
LRMR
$397M
$8.52M 0.84%
259,240
-40,626
-14% -$2.08M
DERM
29
PUT
DELISTED
Dermira, Inc.
DERM
$7.52M 0.74%
+555,300
New +$4.63M
RVLP
30
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$5.4M 0.53%
1,500,000
– –
ARRY
31
CALL
DELISTED
Array Biopharma Inc
ARRY
$4.88M 0.48%
+200,000
New +$4.16M
SVRA icon
32
Savara
SVRA
$1.12B
$4.87M 0.48%
660,366
-1,158,829
-64% -$8.73M
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.5M 0.45%
+309,564
New +$3.95M
KA
34
DELISTED
Kineta, Inc. Common Stock
KA
$4.41M 0.44%
25,000
+3,247
+15% +$1.59M
NVAX icon
35
CALL
Novavax
NVAX
$1.2B
$2.48M 0.25%
225,000
– –
SLDB icon
36
CALL
Solid Biosciences
SLDB
$794M
$1.84M 0.18%
+13,333
New +$3.34M
NVAX icon
37
PUT
Novavax
NVAX
$1.2B
$1.1M 0.11%
+100,000
New +$3.16M
AKBA icon
38
Akebia Therapeutics
AKBA
$354M
$1.08M 0.11%
+131,531
New +$903K
ZYME icon
39
Zymeworks
ZYME
$1.61B
$236K 0.02%
+14,610
New +$227K
STRM
40
DELISTED
Streamline Health Solutions
STRM
$137K 0.01%
8,676
– –
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-40,197
Closed -$2.93M
ARGX icon
42
argenx
ARGX
$54.6B
– –
-18,500
Closed -$1.78M
CYTK icon
43
Cytokinetics
CYTK
$10.5B
– –
-3,173,288
Closed -$20.1M
ENTA icon
44
Enanta Pharmaceuticals
ENTA
$366M
– –
-143,481
Closed -$10.2M
MDGL icon
45
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-27,500
Closed -$3.1M
PTGX icon
46
Protagonist Therapeutics
PTGX
$8.79B
– –
-955,618
Closed -$6.43M
SAGE
47
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-26,000
Closed -$2.49M
SAGE
48
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-26,000
Closed -$2.49M
TGTX icon
49
TG Therapeutics
TGTX
$7.96B
– –
-3,000,000
Closed -$12.3M
VRTX icon
50
PUT
Vertex Pharmaceuticals
VRTX
$121B
– –
-200,000
Closed -$33.1M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Great Point Partners held 55 positions worth $1.01B, up 28% from $791M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Great Point Partners's Q1 2019 filing shows 15 new, 6 increased, 11 reduced and 15 closed positions. Its largest new stake was Ascendis Pharma A/S: 415,000 shares worth $48.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $24.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • Great Point Partners's largest Q1 2019 buy was Ascendis Pharma A/S: 415,000 shares worth $48.8M.
  • Great Point Partners added most to PTC Therapeutics in Q1 2019, an estimated $19.8M increase.
  • Great Point Partners's biggest Q1 2019 reduction was Acadia Pharmaceuticals, cutting an estimated $17.6M.
  • Great Point Partners fully exited Spark Therapeutics, Inc. Common Stock in Q1 2019, selling an estimated $24.7M.
  • Great Point Partners's ten largest holdings make up 55% of its $1.01B portfolio in Q1 2019.
  • Great Point Partners opened 15 new positions and closed 15 in Q1 2019.
  • Great Point Partners's portfolio value rose 28% quarter-over-quarter to $1.01B.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.